Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 23, 2008 Brian Orelli	Leaner Boston Scientific Isn't Looking Healthy Investors are rightfully growing weary of Boston Scientific's ability to cut expenses on flat sales, and they send the stock down.
The Motley Fool October 23, 2008 Brian Orelli	Boston Scientific Should Be Thankful The medical device maker's two-year-old acquisition of Guidant has saved it in the third quarter.
The Motley Fool April 23, 2008 Brian Orelli	Boston Scientific Gets It Done After a rough 2007, it looks like Boston Scientific is turning itself around from the bottom up.
The Motley Fool July 7, 2008 Brian Orelli	And Then There Were 4 The number of drug-eluting stent players in the U.S. doubles with the addition of Medtronic's Endeavor and Abbott Labs' Xience V.
The Motley Fool October 13, 2008 Brian Orelli	Too Little Too Late for Boston Scientific The company gets new stent approved, but it should have happened earlier.
The Motley Fool March 30, 2009 Brian Orelli	Boston Scientific Is Abbott's Sweat Mop Abbott presented data from an ongoing head-to-head trial of Xience and competitor Boston Scientific's Taxus, and the results look even better than the earlier two-year data point.
The Motley Fool April 15, 2009 Brian Orelli	Abbott's on Sale Abbott isn't firing on all cylinders the way it was last year, but things still look fine, and the stock is selling at a discount right now.
The Motley Fool May 14, 2008 Brian Orelli	Abbott Knocks Down Boston Scientific Abbott Labs proves its drug-eluting device works better than its competitors as it presented more data from its ongoing Spirit III trial.
The Motley Fool February 12, 2010 Brian Orelli	Too Bad It's Not in the "Restructuring" Business Shares of Boston Scientific slipped nearly 10% yesterday, after the company released earnings and guidance for this year.
The Motley Fool May 28, 2009 Brian Orelli	Boston Scientific Back in an Atomic Way Can its tiny stent save the day?
The Motley Fool February 3, 2011 Brian Orelli	Add This Stock to Your Show-Me List Wait for the turnaround before investing in Boston Scientific; if it ever comes.
The Motley Fool July 21, 2010 Brian Orelli	Boston Scientific Bounces When you're as beaten-down as Boston Scientific, you seemingly have nowhere to go but up. There's also bankruptcy, but the beleaguered medical device maker seems far from that -- at least for now.
The Motley Fool August 18, 2008 Brian Orelli	Foolish Forecast: Taking Medtronic to Heart In advance of earnings analysts expect Medtronic, with another medical device approval, to boost revenues 17%.
The Motley Fool January 22, 2009 Brian Orelli	Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon.
The Motley Fool February 24, 2010 Brian Orelli	Medtronic Needs to Regrow a Spine Everything else looks fairly good, but the problem I see involves the slight decline in Medtronic's second-largest segment, spinal products.
The Motley Fool February 17, 2009 Brian Orelli	Investors Heart Medtronic The leaner company is more lovable.
The Motley Fool February 5, 2008 Brian Orelli	Boston Scientific Gets Charged Walloped by charges, Boston Scientific posts a loss for the quarter.
The Motley Fool January 29, 2009 Brian Orelli	No Buyer's Remorse at Boston Scientific The pacemakers and defibrillators that Guidant contributed to Boston Scientific's bottom line are still growing strong, but the company had to take a whopping $2.7 billion goodwill writedown because the value of what it purchased has changed.
The Motley Fool July 29, 2011 Brian Orelli	Boston Scientific Shows Me The company has shown it can hit its mark for at least one quarter, but can it last?
The Motley Fool May 21, 2008 Brian Orelli	Medtronic's Endeavors Look Good The medical device maker's new drug-eluting stent helps push up revenue.
The Motley Fool November 24, 2009 Brian Orelli	52-Week Highs! What's Going On? Even with its recent leap, this stock may belong in your portfolio. Medtronic raised earnings guidance today after a fairly strong quarter, and the stock is hitting new 52-week highs.
The Motley Fool August 20, 2008 Brian Orelli	Medtronic Muddles Through The medical device maker manages double-digit growth in a tough market.
The Motley Fool May 29, 2008 Brian Orelli	Medtronic Sticks It to Boston Scientific Medtronic wins the medical-device patent duel with Boston Scientific.
The Motley Fool October 25, 2007 Brian Orelli	Time to Invest in Stents? Stent devices have seen slumping sales over the last few years. Is it time now to invest in the companies that produce them?
The Motley Fool October 20, 2009 Robert Steyer	The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it.
The Motley Fool April 27, 2010 Brian Orelli	Boston Scientific's "Challenging" Quarter Boston Scientific fixed its paperwork problem with the Food and Drug Administration earlier this month, but the resulting recall took its toll on first-quarter profits nonetheless.
The Motley Fool May 27, 2010 Brian Orelli	Ever-Evolving Stent Technology (and How to Profit From It) Stay ahead of the curve.
The Motley Fool January 11, 2008 Brian Orelli	Boston Scientific Lives Below Its Means Cost-cutting efforts should help turn the medical-device making company around in 2008.
The Motley Fool August 26, 2008 Brian Orelli	Rapid Exchange of Fire Competitors try to block Abbott's patent extension.
The Motley Fool February 1, 2010 Brian Orelli	Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost.
The Motley Fool May 28, 2004 W.D. Crotty	Boston Scientific's Stent Gold Mine The company is starting two or more years of high profitability.
The Motley Fool August 6, 2004 Jeff Hwang	Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share?
The Motley Fool May 25, 2010 Brian Orelli	Medtronic Gets Tossed Out With the Bathwater A bad day to report good news.
The Motley Fool August 25, 2009 Brian Orelli	Medtronic Takes the Road Less Traveled It looks like this medical devices company is healthy again.
The Motley Fool April 19, 2005 Stephen D. Simpson	Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good.
The Motley Fool January 6, 2009 Brian Orelli	Boston Scientific Gets Gussied Up Boston Scientific is buying it's current partner, Ireland-based Labcoat.
The Motley Fool February 2, 2004 Alyce Lomax	Boston Scientific's Stent Hopes Nice quarter, but all eyes should be on the Taxus stent.
The Motley Fool December 31, 2007 Brian Orelli	Boston Scientific Restarts Its Heart Boston Scientific receives European approval for its defibrillator, giving the company a revenue boost even if the U.S. approval is delayed.
The Motley Fool July 19, 2005 Stephen D. Simpson	Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note.
The Motley Fool March 8, 2005 Stephen D. Simpson	The Stent Wars Continue Although Boston Scientific and Johnson & Johnson have been beating each other silly for market share, recent clinical data suggest little functional difference between drug-coated stents.
The Motley Fool October 15, 2008 Brian Orelli	Abbott's Stents Aren't (That) Important Abbott's shareholders shouldn't be too focused on drug-eluting stents.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Boston Scientific Regains Consciousness Recent Boston Scientific results show glimmers of hope. At current prices, the risk/reward tradeoff appears favorable enough to warrant a full checkup on the stock.
The Motley Fool January 12, 2007 Billy Fisher	Big Week at Boston Scientific The company's off to a great start so far for 2007. Investors, take note.
The Motley Fool July 26, 2004 W.D. Crotty	Boston Scientific on the Rebound The medical device maker posts robust earnings, softening the blow of the stent delivery system recall.
The Motley Fool July 17, 2008 Brian Orelli	Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release
The Motley Fool October 14, 2005 Stephen D. Simpson	Boston's Stunts With Stents Tough domestic stent competition is weighing on results from one-trick pony Boston Scientific. The company is in a transitional period and that's at least part of why the stock is down where it is.
The Motley Fool February 24, 2009 Brian Orelli	Medtronic Hearts Acquisitions Medical device maker Medtronic pays a little over $1 billion for two acquisitions in one day.
The Motley Fool February 5, 2007 Ryan Fuhrmann	Boston Scientific's Unscientific Outlook There's still uncertainty as the med-tech company blends an acquisition and deals with controversy. Investors, take note.
The Motley Fool July 6, 2007 Billy Fisher	Medtronic: For the Broken-Hearted Promising clinical trial could bring a new Medtronic stent to market. Investors, take note.
The Motley Fool April 8, 2005 Stephen D. Simpson	Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse?